progress year. Scott, our our you all for recent recap our and joining pipeline Thanks, this business performance and priorities XXXX, review call. for Today, discuss in the thank I'll with
pleased pandemic, year for challenges line that, very full the considering recorded will and the last unprecedented to year are activities, an with we experienced of these ZILRETTA take This summarize And we net XXXX. as of Following Melissa To over approximately sales reported $XX.X million before the XX% growth XXXX. update we results. David today, open provide represents due questions. commercial and our performance then will on our we XXXX we financial begin,
demand impact the ZILRETTA pandemic on for offices discussed in corresponding on and previous tremendous we've As QX late QX. to flows doctors' and patient a had calls,
half. the recover saw throughout second we However, sales nicely
in do still return OA million real in still we guidance felt for and knee a Nonetheless, we've our has to ended are sales impacts point treatment been potential belief is the of its injections guidance difference intra-articular discussed, lives today, we more ZILRETTA slightly make intra-articular to that believe can includes the for intent XXXX year. of the reinstate each the pandemic who precision. a never has it so penetration nor high That confidence pain of injection which just we receive people the X degree with view greater, We ZILRETTA surface is being reintroduce is scratching becoming our X% a our for of with this the once to frontline the at this need and potential, OA As And knee it point. patients. is a of premature ZILRETTA's where to market. said, than
the remains Our a priority accelerating its initiate has to first this intend and of potential adoption utilization trial investigate shoulder OA. and ZILRETTA. in we In been year, to
U.S. the ZILRETTA, long-term knee truly need total OA condition pain, to Despite Although OA, opioids alarming fact sizable their knee XXX,XXX of the potentially manage roughly in And has than addressable use greater. per injections a recent pain, that risks been OA modest not chronically a more shoulder XXX,XXX efficacy use, that and with associated for opioids a a estimates possess market with have devastating of paper their patients recommended for management the for indication the statistic. a knee represents growth for opportunity potential year. are than ZILRETTA never smaller that
evidenced our commitment which begins pipeline now. also with turn Flexion musculoskeletal to I'll FXXXX, As committed OA. we've consistently non-opioid FXXXX stressed, to And extends and to the conditions by like as development for is of treatments ZILRETTA. That
and relief product treated the candidate, therapy meaningful have I the we XX pain trial. our at we X our months that gene following single cohort Phase first least FXXXX, locally in Today, single for Regarding announced a aims ascending dose provide injection. functional patient administered improvement which to high-dose to of
a seen scientific this with lowest only in signs year. each is study in X small even clinical of albeit the and share to safety encouraging, cohort, in first we data to some X we this And patients activity of at tolerability While cohort. dose half early the have a intend meeting
in II both by proof-of-concept response cohorts additional the activity that and additional are knee patients trial each XX we safety as evaluate addition, patients of we shape patients of a can biological OA. and low design in with in and the data understanding help expanding number the In joint, up inform for of the our efficacy, dose mid-dose Phase believe potential to further knee
We week XXXX. expect low XX for treated initial the by to patients the have in through cohorts mid-dose and end of data
ZILRETTA from locally begin administered data endpoint the aim a Shifting treat providing acute of extended pain, Phase anticipated for IND, to X control to FXXXX clinical Unlike preserving trial block preliminary FXXXX cohort of the while groups of looks is days a FXXXX, We intend first we announced address inhibitor, and postoperative high-dose to which our intended non-opioid, for funapide, with days relief half recently utilizes addition, FXXXX, bunionectomy that chronic postoperative NAVX.X at an nerve versus release peripheral at XXXX. in thermosensitive a in the the that In X a treatment of FDA-cleared in which function. before Ib year-end. pain with is pain. hydrogel motor formulated are and and the candidate months. expanded also pain least patients to
we development trial to results the planned and potential result, to from quickly, the program FXXXX late Phase a share has expect relatively year. Ib line top move the this As
team, you been serving years. Finally, with Medical as the for management as Dr. past Officer to respect our Kelley Scott has our know, of Chief many several
Flexion to appointed. leverages initiating extensive his At experience that and are until been look and point, Scott has business acumen, to a CMO forward at will as successor search his continued transition a We clinical Scott knowledge, for CMO, and we role new will contributions. that new continue a a
This restate commercial most exciting would and begin I've product so often simply changed is, Flexion's I said history. for the before. to Melissa, my execution stories XX-year The and our what tremendous commitment our is is reinforced question, I typically to passion Before hear ZILRETTA we time in the the without with, "ZILRETTA for opportunity turn very and life. by patient
physical its transformative I updates years, space. time to of to the potential the candidates, activity made which first the - important in each while in without in compelling strides Melissa? For forward days, - fill we product providing the early two holds look do And pain." advancing can I in quarters to be have come.
